Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease

Abstract Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. The use of drug delivery systems (DDS) includes micelles, liposomes, polymeric nanoparticles, dendrimers, carbon nanotubes, and crystalline metals. Nano-DD...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology 2017-09, Vol.70 (3), p.206-211
Main Authors: Matoba, Tetsuya, MD, PhD, Koga, Jun-ichiro, MD, PhD, Nakano, Kaku, PhD, Egashira, Kensuke, MD, PhD, Tsutsui, Hiroyuki, MD, PhD, FJCC
Format: Article
Language:English
Subjects:
Animals
Atherosclerosis - drug therapy
Cardiovascular
Coronary artery disease
Drug Delivery Systems
Humans
Inflammation
Macrophage
Monocyte
Nanomedicine
Nanoparticles - administration & dosage
Nanoparticles - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Administration of drugs and other therapeutic agents has been the central strategy of contemporary medicine for cardiovascular disease. The use of drug delivery systems (DDS) includes micelles, liposomes, polymeric nanoparticles, dendrimers, carbon nanotubes, and crystalline metals. Nano-DDS modify in vivo drug kinetics, depending on (patho)physiological mechanisms such as retard excretion, vascular permeability, and incorporation by mononuclear phagocyte systems, which constitute the ‘passive-targeting’ property of nano-DDS. These properties of nano-DDS are applicable to inflammatory diseases including atherosclerosis. Atherosclerotic plaque destabilization and rupture account for the majority of acute myocardial infarction, for which inflammatory monocytes and macrophages play critical roles. In our experience, polymeric nanoparticles have been delivered to inflammatory monocytes and macrophages in an atherosclerotic mouse model. Nano-DDS loaded with pioglitazone reduced Ly6Chigh inflammatory monocytes and increased Ly6Clow non-inflammatory monocytes in the peripheral blood, and induced M2 macrophage-associated genes in the aorta. Pioglitazone-nanoparticles finally stabilized atherosclerotic plaques assessed by a decrease in the number of buried fibrous caps in the plaque. Application of nano-DDS is a unique and promising approach to prevent life-threatening cardiovascular events including acute myocardial infarction by regulating inflammation in the cardiovascular system.
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2017.03.005